Boiarsky, Rebecca http://orcid.org/0000-0002-8817-8086
Haradhvala, Nicholas J. http://orcid.org/0000-0003-1113-3135
Alberge, Jean-Baptiste
Sklavenitis-Pistofidis, Romanos
Mouhieddine, Tarek H. http://orcid.org/0000-0002-1190-5978
Zavidij, Oksana
Shih, Ming-Chieh
Firer, Danielle
Miller, Mendy
El-Khoury, Habib
Anand, Shankara K.
Aguet, François http://orcid.org/0000-0001-9414-300X
Sontag, David http://orcid.org/0000-0002-5034-7796
Ghobrial, Irene M. http://orcid.org/0000-0001-7361-3092
Getz, Gad http://orcid.org/0000-0002-0936-0753
Funding for this research was provided by:
Multiple Myeloma Research Foundation
EIF | Stand Up To Cancer
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Paul C. Zamecnik Chair in Oncology at the Massachusetts General Hospital Cancer Center
Article History
Received: 10 January 2022
Accepted: 3 October 2022
First Online: 17 November 2022
Competing interests
: F.A. is an inventor on a patent application related to SignatureAnalyzer-GPU (US-2021-0358574); G.G. receives research funds from IBM & Pharmacyclics, and is a founder, consultant, and has privately held equity in Scorpion Therapeutics; G.G. is also an inventor on patent applications filed by the Broad Institute related to MSMuTect and MSMutSig (WO 2019/083594); POLYSOLVER (US-2016-0298185); SignatureAnalyzer-GPU (US-2021-0358574); and MSIDetect (WO 2022/098997 and WO 2022/099004); I.M.G. is a Consultant for AbbVie, Adaptive, Bristol Myers Squibb, Celgene Corporation, Cellectar, CohBar, Curio Science, Dava Oncology, Genentech, Huron Consulting, Karyopharm, Magenta Therapeutics, Menarini Silicon Biosystems, Oncopeptides, Pure Tech Health, Sognef, Takeda, and The Binding Site; an Advisor for Mind Wrap Medical, LLC; and an Advisor and Consultant for Amgen, Aptitude Health, GlaxoSmithKline, GNS Healthcare, Janssen, Pfizer, and Sanofi. I.M.G.’s spouse, William Savage MD, PhD, is CMO and equity holder of Disc Medicine (Private company, not publicly traded); N.J.H. is a consultant for Constellation Pharmaceuticals; D.S. is a consultant for ASAPP, has privately held equity in Curai and ASAPP, and receives research funds from Takeda and IBM; O.Z. is an employee at Constellation Pharmaceuticals. The remaining authors declare no competing interests.